Safety and Efficacy of Low-volume Preparation in the Elderly: Oral Sulfate Solution

Sponsor
Kyung Hee University Hospital at Gangdong (Other)
Overall Status
Completed
CT.gov ID
NCT03112967
Collaborator
(none)
193
1
2
3.8
51.1

Study Details

Study Description

Brief Summary

The investigators will investigate the safety and efficacy of low-volume preparation (Oral Sulfate solution) compared to 4L PEG solution in bowel preparation before colonoscopy.

One aim of this study was to investigate the efficacy of low-volume preparation (Oral Sulfate solution) on bowel preparation before colonoscopy.

Condition or Disease Intervention/Treatment Phase
  • Other: low-volume preparation, oral sulfate solution
  • Other: large-volume preparation, 4L polyethylene glycol
N/A

Detailed Description

Traditionally, polyethylene glycol (PEG) solution, which requires ingestion of a large volume of liquid, has been used and now to a low-volume preparations because of its clear advantages in tolerability. The tolerability of bowel preparations is related to their volume, taste, and side effects, with this being a particular problem in the elderly. Meanwhile, a new oral sulfate solution (OSS, SUPREP, Braintree Laboratories, Braintree, Mass) formulation as an effective low-volume bowel cleansing agent, with a split-dose regimen was recently developed in 2009.

Concerned about being able to better complete ingestion of bowel cleansing agent, OSS with lower volume and improved taste features, as long as it does not sacrifice safety, shuld be a better choice than PEG. Many studies have already looked at the efficacy and safety of OSS compared to PEG in average risk population, but there are no data available in solely at the elderly population. In this context, we hypothesized that OSS could be a good alternative to a standard 4L-PEG solution in elderly patients.

In this report, we describe a multicenter, prospective, investigator-blind, randomized, controlled trial investigating OSS with 4L PEG for efficacy and safety in the elderly.

Study Design

Study Type:
Interventional
Actual Enrollment :
193 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Other
Official Title:
Safety and Efficacy of Low-volume Preparation in the Elderly: Oral Sulfate Solution vs 4L PEG Dolution
Actual Study Start Date :
Apr 20, 2017
Actual Primary Completion Date :
Aug 13, 2017
Actual Study Completion Date :
Aug 13, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: OSS(Suprep)

Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.

Other: low-volume preparation, oral sulfate solution
Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
Other Names:
  • Suprep
  • Active Comparator: 4L PEG solution(Colyte)

    4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.

    Other: large-volume preparation, 4L polyethylene glycol
    4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
    Other Names:
  • Colyte
  • Outcome Measures

    Primary Outcome Measures

    1. Efficacy in bowel preparation [Up to 2 months]

      The boston bowel preparation scale The BBPS uses a 10-point (0-9) summation scale assessing bowel preparation quality, by a 3 point scoring system of 0 to 3 in 3 segments of the colon (right colon, transverse colon, and left colon), where 0 = ''unprepared colon with mucosa not seen because of solid stool,'' 1 = ''portion of colonic mucosa of the segment seen, but other areas not well seen due to staining, residual stool, and/or opaque liquid,'' 2 = ''minor amount of residual staining, stool, and/or opaque liquid, but colonic mucosa of the segment seen well,'' and 3 = ''entire colonic mucosa seen well with no residual staining, stool or opaque liquid.'' An adequate bowel preparation was defined by a total BBPS score ≥ 6 with all segment scores ≥ 2, and excellent cleansing was considered as a score of > 7.

    Secondary Outcome Measures

    1. Adverse events [Up to 2 months]

      Proportion of adverse events. Adverse events recorded on the questionnaires included nausea, vomiting, abdominal pain, bloating, sleep disturbance, numbness, weakness/faint feeling, fecal incontinence, and thirsty. Blood samples were taken at the screening visit and the day of the procedure and were analysed for serum electrolytes (sodium, potassium, chloride, calcium, phosphate and magnesium), blood urea nitrogen (BUN), creatinine and glomerular filtration rate (GFR). Incident kidney injury was defined as a 25% increase in serum creatinine levels or longitudinal significant change in estimated glomerular filtration rate.

    2. compliance and acceptability [Up to 2 months]

      proportion of patients willingness

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    All participants from 65 to 75 age

    Exclusion Criteria:
    1. Underwent Colorectal surgery

    2. CHF, Acute MI <6 months

    3. ASA class III =<

    4. LC, CRF, Ascite, IBD, or Severe inflammatory state

    5. Severe constipation (Bowel movement 3/wk > or Taking stool softener)

    6. Disabled person physically or mentally

    7. Refuse consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Internal Medicine, Kyung Hee University College of Medicine Seoul Korea, Republic of 05278

    Sponsors and Collaborators

    • Kyung Hee University Hospital at Gangdong

    Investigators

    • Principal Investigator: Min Seob Kwak, MD,PhD, KyungHee university hospital at Gangdong

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Min Seob Kwak, Clinical associate professor, Kyung Hee University Hospital at Gangdong
    ClinicalTrials.gov Identifier:
    NCT03112967
    Other Study ID Numbers:
    • 2016-03-021
    First Posted:
    Apr 13, 2017
    Last Update Posted:
    Aug 16, 2017
    Last Verified:
    Aug 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Aug 16, 2017